Healthcare [ 7/13 ] | Biotechnology [ 61/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 9, 23 | -0.48 Increased by +11.11% | -0.52 Increased by +7.69% |
| Aug 9, 23 | -0.48 Decreased by -4.35% | -0.49 Increased by +2.04% |
| May 11, 23 | -0.46 Decreased by -4.55% | -0.54 Increased by +14.81% |
| Mar 15, 23 | -0.55 Increased by +78.09% | -0.52 Decreased by -5.77% |
| Nov 10, 22 | -0.54 Decreased by -116% | -0.51 Decreased by -5.88% |
| Aug 11, 22 | -0.46 Increased by +98.39% | -0.46 |
| May 12, 22 | -0.44 Increased by +97.87% | -0.44 |
| Mar 23, 22 | -2.51 Increased by +84.92% | -0.39 Decreased by -543.59% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -18.51 M Decreased by -17.56% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -18.3 M Decreased by -39.47% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -15.16 M Decreased by -17.89% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -41.81 M Decreased by -259.36% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -15.75 M Decreased by -78.17% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -13.12 M Decreased by -48.22% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -12.86 M Decreased by -116.96% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -11.63 M Decreased by -137.09% | Decreased by N/A% Decreased by N/A% |
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette"guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.